公开(公告)号：US20230417748A1

公开(公告)日：2023-12-28

申请号：US18035235

申请日：2021-11-05

Applicant: GREEN CROSS CORPORATION ,  MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH

Inventor： Dong-Sik KIM ,  Sua LEE ,  Shin A JANG ,  Jihoon KANG ,  KI Joon CHO ,  Soo Bin PARK ,  Young Woo HAN ,  Hyemi NAM ,  Mi Young OH ,  Jee Boong LEE ,  Jihye RYU ,  Mun Kyung KIM ,  Jeewon LEE

IPC: G01N33/569 ,  C07K16/10 ,  A61K47/68

CPC classification number: G01N33/56983 ,  C07K16/1003 ,  A61K47/6841 ,  G01N2333/165 ,  G01N2469/10 ,  C07K2317/56 ,  C07K2317/33 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/732 ,  C07K2317/73

Abstract: Provided are a coronavirus spike (S) protein-specific antibody and use thereof.

公开(公告)号：US20220162310A1

公开(公告)日：2022-05-26

申请号：US17602511

申请日：2020-05-22

Applicant: GREEN CROSS CORPORATION ,  MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH

Inventor： Hye-Young PARK ,  Eun Jung SONG ,  Eun Hee LEE ,  Hye In YUM ,  Hye Mi NAM ,  Mun Kyung KIM ,  Jee Won LEE ,  Joong Hyuk SHEEN ,  Min Kyu HUR ,  So Jung LIM ,  Ok Jae LIM ,  Yang Mi LIM ,  Jong Hwa WON

IPC: C07K16/28 ,  A61P35/00 ,  A61K45/06 ,  A61K39/395

Abstract: The present invention relates to: an antibody to T cell Immunoreceptor with Ig and Tyrosine-Based Inhibitory Motif Domains (TIGIT), or an antigen-binding fragment thereof; a nucleic acid encoding same; a vector carrying the nucleic acid; a cell transformed with the vector; a method for producing the antibody or the antigen-binding fragment thereof; and a composition and a composition for combined administration, which comprise same and are for preventing or treating cancer.

公开(公告)号：US20220135679A1

公开(公告)日：2022-05-05

申请号：US17431218

申请日：2020-04-06

Applicant: GREEN CROSS CORPORATION

Inventor： Jae Chan PARK ,  Eun Jung SONG ,  So Jung LIM ,  Jae-Chul LEE ,  Hae Naem KWON ,  Su A LEE ,  Ok Jae LIM ,  Mun Kyung KIM ,  Hyun Jung CHO ,  Gil-Jung KIM ,  Jee Won LEE ,  Sung Keun KIM ,  Jong Wha WON ,  Shin A JANG

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/30

Abstract: A bispecific anti-GPNMB/anti-CD3 antibody specifically binds to CD3 (cluster of differentiation 3) and GPNMB (glycoprotein non-metastatic melanoma protein B) and uses thereof are disclosed. The bispecific antibody shows high affinity and specificity to CD3 and GPNMB and thus can induce death of cancer cells expressing GPNMB and inhibit proliferation thereof. Therefore, the bispecific antibody can be used as an effective therapeutic agent for cancers expressing GPNMB.